Andexanet alfa and 4F-PCC use in patients hospitalised with an anticoagulant-related major bleed

Study identifier:D9603R00004

ClinicalTrials.gov identifier:NCT05548777

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Andexanet alfa and 4F-PCC use in patients hospitalised with an anticoagulant-related major bleed

Medical condition

Anticoagulant-related major bleed

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Actual enrollment

5480

Study type

Observational

Age

18 Years - 130 Years

Date

Study Start Date: 15 Sept 2022
Primary Completion Date: 20 Dec 2022
Study Completion Date: 20 Dec 2022

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Jan 2023 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

Outcomes Insights

Inclusion and exclusion criteria